

MARKET REPORT



Physician Views: New data for Novartis LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Physician Views: New data for Novartis LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Physician Views: New data for Novartis LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

Scope

The potential blockbuster status of Novartis' LCZ696 has seemingly been cemented in the eyes of the Street thanks to solid results from the Phase III PARADIGM-HF study that were presented over the weekend.

Indeed, the chronic heart failure agent is believed to represent both a significant growth driver for Novartis as well as, alongside the PCSK9 class of dyslipidaemia products, among the first in a new wave of medicines in late-stage development at Big Pharma for cardiovascular indications.

Data from the PARADIGM-HF trial had been highly anticipated ever since Novartis announced in March that the study was being stopped after LCZ696 significantly reduced the primary composite endpoint of time-to-first occurrence of either cardiovascular death or heart failure hospitalisation compared to the standard ACE inhibitor enalapril.

Based on the reaction from analysts, the full data package did not disappoint. According to Bank of America Merrill Lynch analyst Graham Parry, "in our opinion, the data are impressive with a 20-percent reduction in CV death and 16 percent reduction in overall mortality and reassuring safety profile that support FDA approval and widespread use."

"We believe our \$3 billion un-risk adjusted peak sales forecast, which assumes 30 percent penetration in the 6 million US CHF patients and 20 percent in the 6.5 million EU patients, looks increasingly conservative in the light of presented data," Parry added.

Novartis itself is doing little to lower expectations about the programme. "It will be possibly the most exciting launch the company has ever had," Novartis division head David Epstein told an investor meeting.

However, despite LCZ696's clear efficaciousness and relatively clean safety profile, Novartis will be entering a cardiovascular marketplace where price-sensitivity has become increasingly important, a consideration that will undoubtedly play a role in the company's price-setting calculus.

Based on the new data, JP Morgan analyst Richard Vosser believes LCZ696 has "multi-blockbuster potential" and said he is upping his 2020 sales forecast to \$6 billion from \$5 billion.

Purchase Reasons

Thus, FirstWord polled cardiologists in the US and EU5 about their thoughts on the PARADIGM-HF data and how LCZ696 is likely to be used in the real world. Specifically we are asking them...

Amgen recently filed a marketing application with the FDA for ivabradine, a drug already marketed outside the US for heart failure. Given the emergence of LCZ696 (predicted launched in late 2015) and lingering questions about ivabradine's safety, roughly what percentage of patients would you expect to use ivabradine in 18 months from now?Additional Details

Publisher : FirstWord Pharma

Reference :

Number of Pages : 0

Report Format : PDF

Publisher Information :

FirstWord

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

How to Buy...Physician Views: New data for Novartis LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?**Option 1 - Online**

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/153>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$695** | Single User Price
- \$1395** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.